SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Berthet Pascaline)
 

Search: WFRF:(Berthet Pascaline) > (2007-2009) > Nogues Catherine > Oral contraceptives...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group

Brohet, Richard M. (author)
Goldgar, David E. (author)
Easton, Douglas F. (author)
show more...
Antoniou, Antonis C. (author)
Andrieu, Nadine (author)
Chang-Claude, Jenny (author)
Peock, Susan (author)
Eeles, Rosalind A. (author)
Cook, Margaret (author)
Chu, Carol (author)
Nogues, Catherine (author)
Lasset, Christine (author)
Berthet, Pascaline (author)
Meijers-Heijboer, Hanne (author)
Gerdes, Anne-Marie (author)
Olsson, Håkan (author)
Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
Caldes, Trinidad (author)
van Leeuwen, Flora E. (author)
Rookus, Matti A. (author)
show less...
 (creator_code:org_t)
2007
2007
English.
In: Journal of Clinical Oncology. - 1527-7755. ; 25:25, s. 3831-3836
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Purpose Earlier studies have shown that endogenous gonadal hormones play an important role in the etiology of breast cancer among BRCA1/ 2 mutation carriers. So far, little is known about the safety of exogenous hormonal use in mutation carriers. In this study, we examined the association between oral contraceptive use and risk of breast cancer among BRCA1/ 2 carriers. Patients and Methods In the International BRCA1/ 2 Carrier Cohort study ( IBCCS), a retrospective cohort of 1,593 BRCA1/ 2 mutation carriers was analyzed with a weighted Cox regression analysis. Results We found an increased risk of breast cancer for BRCA1/ 2 mutation carriers who ever used oral contraceptives ( adjusted hazard ratio [ HR] = 1.47; 95% CI, 1.16 to 1.87). HRs did not vary according to time since stopping use, age at start, or calendar year at start. However, a longer duration of use, especially before first full- term pregnancy, was associated with an increased risk of breast cancer for both BRCA1 and BRCA2 mutation carriers ( 4 or more years of use before first full-term pregnancy: HR = 1.49 [ 95% CI, 1.05 to 2.11] for BRCA1 carriers and HR = 2.58 [ 95% CI, 1.21 to 5.49] for BRCA2 carriers). Conclusion No evidence was found among BRCA1/ 2 mutation carriers that current use of oral contraceptives is associated with risk of breast cancer more strongly than is past use, as is found in the general population. However, duration of use, especially before first full- term pregnancy, may be associated with an increasing risk of breast cancer among both BRCA1 and BRCA2 mutation carriers.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Oral Contraceptives Breast Cancer International BRCA1/2 EMBRACE GENEPSO GEO-HEBON IBCCS

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view